Nivolumab in previously untreated melanoma without BRAF mutation.

Abstract

BACKGROUND Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study. METHODS We randomly assigned 418 previously… (More)
DOI: 10.1056/NEJMoa1412082

5 Figures and Tables

Topics

  • Blog articles referencing this paper

  • Presentations referencing similar topics